Podium to Practice: Recent Updates on the Treatment of Breast Cancer from the 2021 San Antonio Breast Cancer Annual Meeting
Recent Updates on the Treatment of Breast Cancer from the 2021 San Antonio Breast Cancer Annual Meeting
Release Date: January 31, 2022
Expiration Date: January 30, 2023
Community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with breast cancer.
After participating in this activity, participants should be better able to:
- Assess evidence from recent clinical trial results for patients with HR-positive/HER2-negative early breast cancer
- Discuss targeted therapies for patients with previously treated metastatic HR-positive/HER2-negative breast cancer
- Discuss the current data surrounding systemic treatments for patients with TNBC
- Develop strategies to sequence HER2-directed treatments for patients with HER2-positive breast cancer
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Sara Huvitz, MD, FACP
Director, Breast Cancer Clinical Trials Program, Division of Hematology-Oncology
David Geffen School of Medicine, UCLA
Medical Director, Clinical Research Unit, Jonsson Comprehensive Cancer Center
Los Angeles, California
Consultant: Ambrx, Amgen, Astra Zeneca, Arvinas, Bayer, Cytomx, Daiichi-Sankyo, Dignitana, Genentech/Roche, Gilead, GSK, Immunomedics, Eli Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics/Seagen, Zymeworks, Phoenix Molecular Designs, Ltd.
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Susan F. Smith Center for Women's Cancers
Dana-Farber Cancer Institute
Consultant: AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Bristol-Meyers Squibb, Eisai, Nanostring, Puma, Sanofi, Odonate, Seattle Genetics, Daiichi Sankyo, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Samsung Bioepsis Inc., CytomX, Certara, Mersana Therapeutics, Ellipses Pharma, 4D Pharm, OncoSec Medical Incorperated, Chugai Pharmaceuticals, BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis
Contracted Research: AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Exelixis, Bristol-Meyers Squibb, Eisai, Nanostring, Cyclacel, Sanofi, Odonate, Seattle Genetics
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Sanofi Genzyme.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.